

US-10-049-868a-1 (1-359) x US-09-171-945-17 (1-235)

QY 1 GACATGGGCTCACCACTGGCTCTCCAGGAATCATGTCATCTCCAGGGAGAGGTCAAC 60
Db 23 AspIleGluIleThrGlnSerProAlaIleMetSerAlaSerProGlyGluValThr 42

QY 61 ATGACCTGAGTGCAGTCAGTGTAAATTACATGCAGTGGTCCAGCAGGAGTCGGC 120
Db 43 IleThrCysSerAlaSerSerSerValIthrThrTyrMetHisIlePheGlnGlnLysProGly 62

QY 121 ACCTTCCCCAAAGAAGGATTATGACACATCCAACCTGGCTCTGGAGTCCCTGCTCG 180
Db 53 ThrSerProLysLeuIlePileTyrSerThrSerAsnLeuAlaSerGlyValProAlaArg 82

QY 181 CTCACTGGCAGTGGGCTGGGACAGAAATTACACCTGGAAATCAGTAGACTGAGGTGAG 240
Db 83 PheSerGlySerGlySerGlyThrSerThrSerLeuThrIleSerArgMetGluAlaGlu 102

QY 241 GATGTGGGTGTATCTGTCAACAACCTGTAGAGTATCCGCTCACGTTGGGCTGGC 300
Db 103 AspAlaAlaThrTyrTyrCysGlnGlnArgSerThrTyrProLeuThrPheGlyValGly 122

QY 301 ACCAAGCTGGAGCTGAAACGGGCTGATGCTGCACCAACTGTATCCATCTTC 351
Db 123 ThrLysLeuGluIleLysArgThrValAlaAlaProSerValPheIlePhe 139

RESULT 2

5455030-3

; Patent No. 5455030

; APPLICANT: LADNER, ROBERT C.; BIRD, ROBERT E.; HARDMAN, KARL

; TITLE OF INVENTION: IMMUNOTHERAPY USING SINGLE CHAIN

; POLYPEPTIDE BINDING MOLECULES

; NUMBER OF SEQUENCES: 24

; CURRENT APPLICATION DATA:

; APPLICATION NUMBER: US/08/40,440

; FILING DATE: 1-APR-1993

; PRIOR APPLICATION DATA:

; APPLICATION NUMBER: 512,910

; FILING DATE: 25-APR-1990

; APPLICATION NUMBER: 299,617

; FILING DATE: 19-JAN-1989

; APPLICATION NUMBER: 92,110

; FILING DATE: 02-SEP-1987

; APPLICATION NUMBER: 902,971

; FILING DATE: 01-SEP-1986

; SEQ ID NO:3; LENGTH: 215

; SEQ ID NO:3; LENGTH: 215

; SEQ ID NO:3; LENGTH: 215

Alignment Scores:

Pred. No.: 3.01e-45

Score: 445.00

Percent Similarity: 82.76%

Best Local Similarity: 77.59%

Query Match: 66.02%

DB: 6

US-10-049-868A-1 (1-359) x 5455030-3 (1-215)

5455030-3

Alignment Scores:

Pred. No.: 3.11e-45

Score: 445.00

Percent Similarity: 83.62%

Best Local Similarity: 75.00%

Query Match: 66.02%

DB: 2

US-10-049-868A-1 (1-359) x 5455030-3 (1-215)

Db 64 SerGlySerGlySerGlyThrSerLeuIleSerValGluAlaGluAsp 83

QY 244 GTGGGRTGTATTACTGTCAACACTGTAGAGTATCCGCTCACGTTGGTGTGGGAC 303

Db 84 AlaAlaThrTyrTyrCysGlnGlnTyrSerGlyTyrProLeuThrPheGlyAlaGlyThr 103

QY 304 AAGCTGGAGCTGAAACGGGCTGATGCTGCACCAACTGTATCCATCTTC 351

Db 104 LysLeuGluIleLysArgAlaAspAlaAlaProIleValSerIlePhe 119

RESULT 3

US-08-303-569B-5

; Sequence 5, Application US/08303569B

; Patent No. 5859205

; GENERAL INFORMATION:

; APPLICANT: Adair, John R.

; APPLICANT: Athwal, Diljeet S.

; APPLICANT: Emtage, John S.

; TITLE OF INVENTION: Humanised Antibodies

; NUMBER OF SEQUENCES: 31

; CORRESPONDENCE ADDRESS:

; ADDRESSEE: Woodcock Washburn Kurtz Mackiewicz & No. 5859205ris

; STREET: One Liberty Place - 46th Floor

; CITY: Philadelphia

; STATE: PA

; COUNTRY: USA

; ZIP: 19103

; COMPUTER READABLE FORM:

; MEDIUM TYPE: Floppy disk

; COMPUTER: IBM PC compatible

; OPERATING SYSTEM: PC-DOS/MS-DOS

; SOFTWARE: PatentIn Release.#1.0, Version #1.25

; CURRENT APPLICATION DATA:

; APPLICATION NUMBER: US/08/303,569B

; FILING DATE: 07-SEP-1994

; CLASSIFICATION:

; ATTORNEY/AGENT INFORMATION:

; NAME: Trujillo, Doreen Yatko

; REGISTRATION NUMBER: 35,719

; REFERENCE/DOCKET NUMBER: CARP-0032

; TELECOMMUNICATION INFORMATION:

; TELEPHONE: (215) 568-3100

; TELEFAX: (215) 568-3439

; INFORMATION FOR SEQ ID NO: 5:

; SEQUENCE CHARACTERISTICS:

; LENGTH: 235 amino acids

; TYPE: amino acid

; TOPOL: linear

; MOLECULE TYPE: protein

; MOLECULE TYPE: protein

US-08-303-569B-5

Alignment Scores:

Pred. No.: 3.11e-45

Score: 445.00

Percent Similarity: 83.62%

Best Local Similarity: 75.00%

Query Match: 66.02%

DB: 2

US-10-049-868A-1 (1-359) x US-08-303-569B-5 (1-235)

QY 10 CTGACCCAGTCAGCAATCATGTCAGTCAGTCAGGAGGTACCATGACCTGC 69
Db 4 LeuThrGlnSerProAlaIleMetSerAlaSerProGlyGluLysValThrMetThrCys 23

QY 70 AGTGCAGTCAGTGT-----ATTACATGCAGTGGTCCAGCAGGAGTCGGCACC 123
Db 24 ArgAlaSerSerSerValSerSerSerTyrLeuHsIlePheGlnGlnLysSerGlyAla 43

QY 124 TTCCCAAAGAAGGATTATGACACATCCAACCTGGCTCTGGAGTCCTGCTCGCCTC 183
Db 44 SerProLysLeuIlePileTyrSerThrSerAsnLeuIleSerGlyValProAlaArgPhe 63

QY 184 AGTGGCAGTGGCTGGGACAGAATTCCACCTGGAAATCACTGAGTGAAGGCTGAGGAT 243
Db 64 SerProLysArgPileTyrAspThrSerIleLysLeuIleSerGlyValProAlaHisPhe 83

GenCore version 5.1.6
Copyright (c) 1993 - 2004 Compugen Ltd.

OM protein - protein search, using sw model

Run on: October 13, 2004, 12:49:03 ; Search time 28.2625 Seconds
(without alignments)
279.234 Million cell updates/sec

Title: US-10-049-868a-3
Perfect score: 606
Sequence: 1 DIELTQSPAIMSASPGEKVT.....GTKLELKRAADAAPTVSIFKL 119

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 478139 seqs, 66318000 residues

Total number of hits satisfying chosen parameters: 478139

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : Issued_Patents_AA:*

1: /cgn2_6/ptodata/1/iaa/5A_COMB.pep:*

2: /cgn2_6/ptodata/1/iaa/5B_COMB.pep:*

3: /cgn2_6/ptodata/1/iaa/6A_COMB.pep:*

4: /cgn2_6/ptodata/1/iaa/6B_COMB.pep:*

5: /cgn2_6/ptodata/1/iaa/PCTUS_COMB.pep:*

6: /cgn2_6/ptodata/1/iaa/backfile1.pep:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Length	DB ID	Description
1	458	75.6	235	3 US-09-171-945-17
2	445	73.4	215	6 5455030-3
3	445	73.4	235	2 US-08-303-569B-5
4	445	73.4	235	2 US-08-116-247-5
5	445	73.4	235	4 US-09-795-515-5
6	445	73.4	235	4 US-09-348-224-5
7	444	73.3	255	3 US-09-553-498-8
8	444	73.3	255	4 US-09-618-869-8
9	443.5	73.2	213	2 US-08-737-129A-4
10	439	72.4	108	3 US-09-171-945-9
11	427	70.5	256	4 US-09-526-738A-2
12	427	70.5	258	4 US-09-526-738A-4
13	426	70.3	270	2 US-08-652-507-2
14	426	70.3	553	2 US-08-661-052-16
15	426	70.3	553	3 US-09-188-082-16
16	426	70.3	553	3 US-09-364-088-16
17	426	70.3	553	3 US-09-102-716-16
18	425	70.1	223	2 US-08-190-199A-63
19	425	70.1	235	3 US-09-423-439-58
20	425	70.1	236	2 US-08-190-199A-65
21	425	70.0	222	2 US-08-190-199A-67
22	424	70.0	235	2 US-08-190-199A-61
23	424	69.3	106	2 US-08-956-047-33
24	420	69.3	128	2 US-08-956-047-31
25	420	69.3	240	2 US-08-956-047-25
26	420	69.3	281	3 US-09-423-439-44

ALIGNMENTS

RESULT 1
US-09-171-945-17
; Sequence 17, Application US/09171945
; Patent No. 6277599
; GENERAL INFORMATION:
; APPLICANT: Emery, Clive Graham
; APPLICANT: Copley, Clive Graham
; APPLICANT: Edge, Michael Derek
; TITLE OF INVENTION: Monoclonal Antibody to CEA, Conjugates Comprising Said
; TITLE OF INVENTION: Antibody, and Their Therapeutic Use in an Adept System
; FILE REFERENCE: Monoclonal Antibody to CEA
; CURRENT APPLICATION NUMBER: US/09/171,945
; CURRENT FILING DATE: 1998-10-29
; PRIOR APPLICATION NUMBER: GB9703103.3
; PRIOR FILING DATE: 1997-02-14
; PRIOR APPLICATION NUMBER: GB9609405.7
; PRIOR FILING DATE: 1996-05-04
; PRIOR APPLICATION NUMBER: PCT/GB97/01165
; PRIOR FILING DATE: 1997-04-29
; NUMBER OF SEQ ID NOS: 131
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 17
; LENGTH: 235
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: humanized
; US-09-171-945-17
Query Match Best Local Similarity 75.6%; Score 458; DB 3; Length 235;
Matches 90; Conservative 8; Mismatches 19; Indels 0; Gaps 0;
Sequence 1, Appli
Sequence 2, Appli
Sequence 3, Appli
Sequence 4, Appli
Sequence 5, Appli
Sequence 6, Appli
Sequence 7, Appli
Sequence 8, Appli
Sequence 9, Appli
Sequence 10, Appli
Sequence 11, Appli
Sequence 12, Appli
Sequence 13, Appli
Sequence 14, Appli
Sequence 15, Appli
Sequence 16, Appli
Sequence 17, Appli
Sequence 18, Appli
Sequence 19, Appli
Sequence 20, Appli
Sequence 21, Appli
Sequence 22, Appli
Sequence 23, Appli
Sequence 24, Appli
Sequence 25, Appli
Sequence 26, Appli
Sequence 27, Appli
Sequence 28, Appli
Sequence 29, Appli
Sequence 30, Appli
Sequence 31, Appli
Sequence 32, Appli
Sequence 33, Appli
Sequence 34, Appli
Sequence 35, Appli
Sequence 36, Appli
Sequence 37, Appli
Sequence 38, Appli
Sequence 39, Appli
Sequence 40, Appli
Sequence 41, Appli
Sequence 42, Appli
Sequence 43, Appli
Sequence 44, Appli
Sequence 45, Appli
; RESULT 2
; 5455030-3
; Patent No. 5455030
; APPLICANT: LADNER, ROBERT C.; BIRD, ROBERT E.; HARDMAN, KARL
; TITLE OF INVENTION: IMMUNOTHERAPY USING SINGLE CHAIN
; POLYPEPTIDE BINDING MOLECULES
; NUMBER OF SEQUENCES: 24
; CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/08/40,440
 FILING DATE: 1-APR-1993
 PRIORITY APPLICATION DATA:
 APPLICATION NUMBER: 512,910
 FILING DATE: 25-APR-1990
 APPLICATION NUMBER: 299,617
 FILING DATE: 19-JAN-1989
 APPLICATION NUMBER: 92,110
 FILING DATE: 02-SEP-1987
 APPLICATION NUMBER: 902,971
 FILING DATE: 01-SEP-1986
 SEQ ID NO:3:
 LENGTH: 215
 5455030-3

RESULT 4
 US-08-116-247-5
 Sequence 5, Application US/08116247
 Patent No. 5929212

GENERAL INFORMATION:
 APPLICANT: Jolliffe, Linda K.
 APPLICANT: Zivin, Robert A.
 APPLICANT: Adair, John R.
 APPLICANT: Athwal, Diljeet S.
 TITLE OF INVENTION: CD3 Specific Recombinant Antibody
 NUMBER OF SEQUENCES: 29
 CORRESPONDENCE ADDRESS:
 ADDRESSEE: Woodcock Wasburn Kurtz Mackiewicz & No. 5929212ris
 STREET: One Liberty Place - 46th Floor
 CITY: Philadelphia
 STATE: PA
 COUNTRY: USA
 ZIP: 19103

COMPUTER READABLE FORM:
 MEDIUM TYPE: Floppy disk
 COMPUTER: IBM PC compatible
 OPERATING SYSTEM: PC-DOS/MS-DOS
 SOFTWARE: PatentIn Release #1.0, Version #1.25
 CURRENT APPLICATION DATA:
 APPLICATION NUMBER: US/08/116,247
 FILING DATE:
 CLASSIFICATION: 435

PRIOR APPLICATION DATA:
 APPLICATION NUMBER: US 07/743,377
 FILING DATE: 10-OCT-1991
 ATTORNEY/AGENT INFORMATION:
 NAME: Paintin, Francis A.
 REGISTRATION NUMBER: 19,386
 REFERENCE/DOCKET NUMBER: CARP-0011
 TELECOMMUNICATION INFORMATION:
 TELEPHONE: (215) 568-3100
 TELEFAX: (215) 568-3439
 INFORMATION FOR SEQ ID NO: 5:
 SEQUENCE CHARACTERISTICS:
 LENGTH: 235 amino acids
 TYPE: amino acid
 TOPOLOGY: linear
 MOLECULE TYPE: protein
 US-08-116-247-5

RESULT 5
 US-09-795-515-5
 Sequence 5, Application US/09795515
 Patent No. 6632927
 GENERAL INFORMATION:
 APPLICANT: Adair, John R.

Query Match 73.4%; Score 445; DB 2; Length 235;
 Best Local Similarity 75.0%; Pred. No. 3.1e-40;
 Matches 87; Conservative 10; Mismatches 19; Indels 0; Gaps 0;
 US-08-303-569B-5

Query Match 73.4%; Score 445; DB 6; Length 215;
 Best Local Similarity 77.6%; Pred. No. 2.8e-40;
 Matches 90; Conservative 6; Mismatches 18; Indels 2; Gaps 1;
 US-08-303-569B-5

Query Match 73.4%; Score 445; DB 6; Length 215;
 Best Local Similarity 77.6%; Pred. No. 2.8e-40;
 Matches 90; Conservative 6; Mismatches 18; Indels 2; Gaps 1;
 US-08-303-569B-5

QY 2 IELTOSPAIMSASPGEKVTMCSASSSWYHWFQEQSGTPKRIYDTSKLASGVPARL 61
 Db 24 IVLTOSPAIMSASPGEKVTMCSASSSWYHWFQEQSGTPKRIYDTSKLASGVPARF 83

QY 62 SGSGSGTEFTLEISRVAEDVGVYCCQOLVEYPLTGAFTKLELKRAADAPTVSIF 117
 Db 84 RGSGSGTTSYLSITSGMEAEDAATYVCCQWSSNPFITFGSGTKLEINRADTAPTVSIF 139

QY 4 LTOSPAIMSASPGEKVTMCSASSSWYHWFQEQSGTPKRIYDTSKLASGVPARL 61
 Db 4 LTOSPAIMSASPGEKVTMCRASSSVSSYLYHWFQOKSGTSPKRWYDTSKLASGVPARF 63

QY 62 SGSGSGTTSYLSITSGMEAEDAATYVCCQWSSNPFITFGSGTKLEINRADTAPTVSIF 117
 Db 64 SGSGSGTTSYLSITSGMEAEDAATYVCCQWSSNPFITFGSGTKLEINRADTAPTVSIF 119

QY 2 IELTOSPAIMSASPGEKVTMCSASSSWYHWFQEQSGTPKRIYDTSKLASGVPARL 61
 Db 24 IVLTOSPAIMSASPGEKVTMCSASSSWYHWFQEQSGTPKRIYDTSKLASGVPARF 83

QY 62 SGSGSGTEFTLEISRVAEDVGVYCCQOLVEYPLTGAFTKLELKRAADAPTVSIF 117
 Db 84 RGSGSGTTSYLSITSGMEAEDAATYVCCQWSSNPFITFGSGTKLEINRADTAPTVSIF 139

QY 2 IELTOSPAIMSASPGEKVTMCSASSSWYHWFQEQSGTPKRIYDTSKLASGVPARL 61
 Db 24 IVLTOSPAIMSASPGEKVTMCSASSSWYHWFQEQSGTPKRIYDTSKLASGVPARF 83

QY 62 SGSGSGTEFTLEISRVAEDVGVYCCQOLVEYPLTGAFTKLELKRAADAPTVSIF 117
 Db 84 RGSGSGTTSYLSITSGMEAEDAATYVCCQWSSNPFITFGSGTKLEINRADTAPTVSIF 139

QY 2 IELTOSPAIMSASPGEKVTMCSASSSWYHWFQEQSGTPKRIYDTSKLASGVPARL 61
 Db 24 IVLTOSPAIMSASPGEKVTMCSASSSWYHWFQEQSGTPKRIYDTSKLASGVPARF 83

QY 62 SGSGSGTEFTLEISRVAEDVGVYCCQOLVEYPLTGAFTKLELKRAADAPTVSIF 117
 Db 84 RGSGSGTTSYLSITSGMEAEDAATYVCCQWSSNPFITFGSGTKLEINRADTAPTVSIF 139

QY 2 IELTOSPAIMSASPGEKVTMCSASSSWYHWFQEQSGTPKRIYDTSKLASGVPARL 61
 Db 24 IVLTOSPAIMSASPGEKVTMCSASSSWYHWFQEQSGTPKRIYDTSKLASGVPARF 83

QY 62 SGSGSGTEFTLEISRVAEDVGVYCCQOLVEYPLTGAFTKLELKRAADAPTVSIF 117
 Db 84 RGSGSGTTSYLSITSGMEAEDAATYVCCQWSSNPFITFGSGTKLEINRADTAPTVSIF 139

QY 2 IELTOSPAIMSASPGEKVTMCSASSSWYHWFQEQSGTPKRIYDTSKLASGVPARL 61
 Db 24 IVLTOSPAIMSASPGEKVTMCSASSSWYHWFQEQSGTPKRIYDTSKLASGVPARF 83

QY 62 SGSGSGTEFTLEISRVAEDVGVYCCQOLVEYPLTGAFTKLELKRAADAPTVSIF 117
 Db 84 RGSGSGTTSYLSITSGMEAEDAATYVCCQWSSNPFITFGSGTKLEINRADTAPTVSIF 139

QY 2 IELTOSPAIMSASPGEKVTMCSASSSWYHWFQEQSGTPKRIYDTSKLASGVPARL 61
 Db 24 IVLTOSPAIMSASPGEKVTMCSASSSWYHWFQEQSGTPKRIYDTSKLASGVPARF 83

QY 62 SGSGSGTEFTLEISRVAEDVGVYCCQOLVEYPLTGAFTKLELKRAADAPTVSIF 117
 Db 84 RGSGSGTTSYLSITSGMEAEDAATYVCCQWSSNPFITFGSGTKLEINRADTAPTVSIF 139

QY 2 IELTOSPAIMSASPGEKVTMCSASSSWYHWFQEQSGTPKRIYDTSKLASGVPARL 61
 Db 24 IVLTOSPAIMSASPGEKVTMCSASSSWYHWFQEQSGTPKRIYDTSKLASGVPARF 83

QY 62 SGSGSGTEFTLEISRVAEDVGVYCCQOLVEYPLTGAFTKLELKRAADAPTVSIF 117
 Db 84 RGSGSGTTSYLSITSGMEAEDAATYVCCQWSSNPFITFGSGTKLEINRADTAPTVSIF 139

QY 2 IELTOSPAIMSASPGEKVTMCSASSSWYHWFQEQSGTPKRIYDTSKLASGVPARL 61
 Db 24 IVLTOSPAIMSASPGEKVTMCSASSSWYHWFQEQSGTPKRIYDTSKLASGVPARF 83

QY 62 SGSGSGTEFTLEISRVAEDVGVYCCQOLVEYPLTGAFTKLELKRAADAPTVSIF 117
 Db 84 RGSGSGTTSYLSITSGMEAEDAATYVCCQWSSNPFITFGSGTKLEINRADTAPTVSIF 139

QY 2 IELTOSPAIMSASPGEKVTMCSASSSWYHWFQEQSGTPKRIYDTSKLASGVPARL 61
 Db 24 IVLTOSPAIMSASPGEKVTMCSASSSWYHWFQEQSGTPKRIYDTSKLASGVPARF 83

QY 62 SGSGSGTEFTLEISRVAEDVGVYCCQOLVEYPLTGAFTKLELKRAADAPTVSIF 117
 Db 84 RGSGSGTTSYLSITSGMEAEDAATYVCCQWSSNPFITFGSGTKLEINRADTAPTVSIF 139

QY 2 IELTOSPAIMSASPGEKVTMCSASSSWYHWFQEQSGTPKRIYDTSKLASGVPARL 61
 Db 24 IVLTOSPAIMSASPGEKVTMCSASSSWYHWFQEQSGTPKRIYDTSKLASGVPARF 83

QY 62 SGSGSGTEFTLEISRVAEDVGVYCCQOLVEYPLTGAFTKLELKRAADAPTVSIF 117
 Db 84 RGSGSGTTSYLSITSGMEAEDAATYVCCQWSSNPFITFGSGTKLEINRADTAPTVSIF 139

QY 2 IELTOSPAIMSASPGEKVTMCSASSSWYHWFQEQSGTPKRIYDTSKLASGVPARL 61
 Db 24 IVLTOSPAIMSASPGEKVTMCSASSSWYHWFQEQSGTPKRIYDTSKLASGVPARF 83

QY 62 SGSGSGTEFTLEISRVAEDVGVYCCQOLVEYPLTGAFTKLELKRAADAPTVSIF 117
 Db 84 RGSGSGTTSYLSITSGMEAEDAATYVCCQWSSNPFITFGSGTKLEINRADTAPTVSIF 139

QY 2 IELTOSPAIMSASPGEKVTMCSASSSWYHWFQEQSGTPKRIYDTSKLASGVPARL 61
 Db 24 IVLTOSPAIMSASPGEKVTMCSASSSWYHWFQEQSGTPKRIYDTSKLASGVPARF 83

QY 62 SGSGSGTEFTLEISRVAEDVGVYCCQOLVEYPLTGAFTKLELKRAADAPTVSIF 117
 Db 84 RGSGSGTTSYLSITSGMEAEDAATYVCCQWSSNPFITFGSGTKLEINRADTAPTVSIF 139

QY 2 IELTOSPAIMSASPGEKVTMCSASSSWYHWFQEQSGTPKRIYDTSKLASGVPARL 61
 Db 24 IVLTOSPAIMSASPGEKVTMCSASSSWYHWFQEQSGTPKRIYDTSKLASGVPARF 83

QY 62 SGSGSGTEFTLEISRVAEDVGVYCCQOLVEYPLTGAFTKLELKRAADAPTVSIF 117
 Db 84 RGSGSGTTSYLSITSGMEAEDAATYVCCQWSSNPFITFGSGTKLEINRADTAPTVSIF 139

QY 2 IELTOSPAIMSASPGEKVTMCSASSSWYHWFQEQSGTPKRIYDTSKLASGVPARL 61
 Db 24 IVLTOSPAIMSASPGEKVTMCSASSSWYHWFQEQSGTPKRIYDTSKLASGVPARF 83

QY 62 SGSGSGTEFTLEISRVAEDVGVYCCQOLVEYPLTGAFTKLELKRAADAPTVSIF 117
 Db 84 RGSGSGTTSYLSITSGMEAEDAATYVCCQWSSNPFITFGSGTKLEINRADTAPTVSIF 139

QY 2 IELTOSPAIMSASPGEKVTMCSASSSWYHWFQEQSGTPKRIYDTSKLASGVPARL 61
 Db 24 IVLTOSPAIMSASPGEKVTMCSASSSWYHWFQEQSGTPKRIYDTSKLASGVPARF 83

QY 62 SGSGSGTEFTLEISRVAEDVGVYCCQOLVEYPLTGAFTKLELKRAADAPTVSIF 117
 Db 84 RGSGSGTTSYLSITSGMEAEDAATYVCCQWSSNPFITFGSGTKLEINRADTAPTVSIF 139

QY 2 IELTOSPAIMSASPGEKVTMCSASSSWYHWFQEQSGTPKRIYDTSKLASGVPARL 61
 Db 24 IVLTOSPAIMSASPGEKVTMCSASSSWYHWFQEQSGTPKRIYDTSKLASGVPARF 83

QY 62 SGSGSGTEFTLEISRVAEDVGVYCCQOLVEYPLTGAFTKLELKRAADAPTVSIF 117
 Db 84 RGSGSGTTSYLSITSGMEAEDAATYVCCQWSSNPFITFGSGTKLEINRADTAPTVSIF 139

QY 2 IELTOSPAIMSASPGEKVTMCSASSSWYHWFQEQSGTPKRIYDTSKLASGVPARL 61
 Db 24 IVLTOSPAIMSASPGEKVTMCSASSSWYHWFQEQSGTPKRIYDTSKLASGVPARF 83

QY 62 SGSGSGTEFTLEISRVAEDVGVYCCQOLVEYPLTGAFTKLELKRAADAPTVSIF 117
 Db 84 RGSGSGTTSYLSITSGMEAEDAATYVCCQWSSNPFITFGSGTKLEINRADTAPTVSIF 139

QY 2 IELTOSPAIMSASPGEKVTMCSASSSWYHWFQEQSGTPKRIYDTSKLASGVPARL 61
 Db 24 IVLTOSPAIMSASPGEKVTMCSASSSWYHWFQEQSGTPKRIYDTSKLASGVPARF 83

QY 62 SGSGSGTEFTLEISRVAEDVGVYCCQOLVEYPLTGAFTKLELKRAADAPTVSIF 117
 Db 84 RGSGSGTTSYLSITSGMEAEDAATYVCCQWSSNPFITFGSGTKLEINRADTAPTVSIF 139

QY 2 IELTOSPAIMSASPGEKVTMCSASSSWYHWFQEQSGTPKRIYDTSKLASGVPARL 61
 Db 24 IVLTOSPAIMSASPGEKVTMCSASSSWYHWFQEQSGTPKRIYDTSKLASGVPARF 83

QY 62 SGSGSGTEFTLEISRVAEDVGVYCCQOLVEYPLTGAFTKLELKRAADAPTVSIF 117
 Db 84 RGSGSGTTSYLSITSGMEAEDAATYVCCQWSSNPFITFGSGTKLEINRADTAPTVSIF 139

QY 2 IELTOSPAIMSASPGEKVTMCSASSSWYHWFQEQSGTPKRIYDTSKLASGVPARL 61
 Db 24 IVLTOSPAIMSASPGEKVTMCSASSSWYHWFQEQSGTPKRIYDTSKLASGVPARF 83

QY 62 SGSGSGTEFTLEISRVAEDVGVYCCQOLVEYPLTGAFTKLELKRAADAPTVSIF 117
 Db 84 RGSGSGTTSYLSITSGMEAEDAATYVCCQWSSNPFITFGSGTKLEINRADTAPTVSIF 139

QY 2 IELTOSPAIMSASPGEKVTMCSASSSWYHWFQEQSGTPKRIYDTSKLASGVPARL 61
 Db 24 IVLTOSPAIMSASPGEKVTMCSASSSWYHWFQEQSGTPKRIYDTSKLASGVPARF 83

QY 62 SGSGSGTEFTLEISRVAEDVGVYCCQOLVEYPLTGAFTKLELKRAADAPTVSIF 117
 Db 84 RGSGSGTTSYLSITSGMEAEDAATYVCCQWSSNPFITFGSGTKLEINRADTAPTVSIF 139

QY 2 IELTOSPAIMSASPGEKVTMCSASSSWYHWFQEQSGTPKRIYDTSKLASGVPARL 61
 Db 24 IVLTOSPAIMSASPGEKVTMCSASSSWYHWFQEQSGTPKRIYDTSKLASGVPARF 83

QY 62 SGSGSGTEFTLEISRVAEDVGVYCCQOLVEYPLTGAFTKLELKRAADAPTVSIF 117
 Db 84 RGSGSGTTSYLSITSGMEAEDAATYVCCQWSSNPFITFGSGTKLEINRADTAPTVSIF 139

QY 2 IELTOSPAIMSASPGEKVTMCSASSSWYHWFQEQSGTPKRIYDTSKLASGVPARL 61
 Db 24 IVLTOSPAIMSASPGEKVTMCSASSSWYHWFQEQSGTPKRIYDTSKLASGVPARF 83

QY 62 SGSGSGTEFTLEISRVAEDVGVYCCQOLVEYPLTGAFTKLELKRAADAPTVSIF 117
 Db 84 RGSGSGTTSYLSITSGMEAEDAATYVCCQWSSNPFITFGSGTKLEINRADTAPTVSIF 139

QY 2 IELTOSPAIMSASPGEKVTMCSASSSWYHWFQEQSGTPKRIYDTSKLASGVPARL 61
 Db 24 IVLTOSPAIMSASPGEKVTMCSASSSWYHWFQEQSGTPKRIYDTSKLASGVPARF 83

QY 62 SGSGSGTEFTLEISRVAEDVGVYCCQOLVEYPLTGAFTKLELKRAADAPTVSIF 117
 Db 84 RGSGSGTTSYLSITSGMEAEDAATYVCCQWSSNPFITFGSGTKLEINRADTAPTVSIF 139

QY 2 IELTOSPAIMSASPGEKVTMCSASSSWYHWFQEQSGTPKRIYDTSKLASGVPARL 61
 Db 24 IVLTOSPAIMSASPGEKVTMCSASSSWYHWFQEQSGTPKRIYDTSKLASGVPARF 83

QY 62 SGSGSGTEFTLEISRVAEDVGVYCCQOLVEYPLTGAFTKLELKRAADAPTVSIF 117
 Db 84 RGSGSGTTSYLSITSGMEAEDAATYVCCQWSSNPFITFGSGTKLEINRADTAPTVSIF 139

QY 2 IELTOSPAIMSASPGEKVTMCSASSSWYHWFQEQSGTPKRIYDTSKLASGVPARL 61
 Db 24 IVLTOSPAIMSASPGEKVTMCSASSSWYHWFQEQSGTPKRIYDTSKLASGVPARF 83

QY 62 SGSGSGTEFTLEISRVAEDVGVYCCQOLVEYPLTGAFTKLELKRAADAPTVSIF 117
 Db 84 RGSGSGTTSYLSITSGMEAEDAATYVCCQWSSNPFITFGSGTKLEINRADTAPTVSIF 139

QY 2 IELTOSPAIMSASPGEKVTMCSASSSWYHWFQEQSGTPKRIYDTSKLASGVPARL 61
 Db 24 IVLTOSPAIMSASPGEKVTMCSASSSWYHWFQEQSGTPKRIYDTSKLASGVPARF 83

QY 62 SGSGSGTEFTLEISRVAEDVGVYCCQOLVEYPLTGAFTKLELKRAADAPTVSIF 117
 Db 84 RGSGSGTTSYLSITSGMEAEDAATYVCCQWSSNPFITFGSGTKLEINRADTAPTVSIF 139

QY 2 IELTOSPAIMSASPGEKVTMCSASSSWYHWFQEQSGTPKRIYDTSKLASGVPARL 61
 Db 24 IVLTOSPAIMSASPGEKVTMCSASSSWYHWFQEQSGTPKRIYDTSKLASGVPARF 83

QY 62 SGSGSGTEFTLEISRVAEDVGVYCCQOLVEYPLTGAFTKLELKRAADAPTVSIF 117
 Db 84 RGSGSGTTSYLSITSGMEAEDAATYVCCQWSSNPFITFGSGTKLEINRADTAPTVSIF 139

QY 2 IELTOSPAIMSASPGEKVTMCSASSSWYHWFQEQSGTPKRIYDTSKLASGVPARL 61
 Db 24 IVLTOSPAIMSASPGEKVTMCSASSSWYHWFQEQSGTPKRIYDTSKLASGVPARF 83

QY 62 SGSGSGTEFTLEISRVAEDVGVYCCQOLVEYPLTGAFTKLELKRAADAPTVSIF 117
 Db 84 RGSGSGTTSYLSITSGMEAEDAATYVCCQWSSNPFITFGSGTKLEINRADTAPTVSIF 139

QY 2 IELTOSPAIMSASPGEKVTMCSASSSWYHWFQEQSGTPKRIYDTSKLASGVPARL 61
 Db 24 IVLTOSPAIMSASPGEKVTMCSASSSWYHWFQEQSGTPKRIYDTSKLASGVPARF 83

QY 62 SGSGSGTEFTLEISRVAEDVGVYCCQOLVEYPLTGAFTKLELKRAADAPTVSIF 117
 Db 84 RGSGSGTTSYLSITSGMEAEDAATYVCCQWSSNPFITFGSGTKLEINRADTAPTVSIF 139

QY 2 IELTOSPAIMSASPGEKVTMCSASSSWYHWFQEQSGTPKRIYDTSKLASGVPARL 61
 Db 24 IVLTOSPAIMSASPGEKVTMCSASSSWYHWFQEQSGTPKRIYDTSKLASGVPARF 83

QY 62 SGSGSGTEFTLEISRVAEDVGVYCCQOLVEYPLTGAFTKLELKRAADAPTVSIF 117
 Db 84 RGSGSGTTSYLSITSGMEAEDAATYVCCQWSSNPFITFGSGTKLEINRADTAPTVSIF 139

QY 2 IELTOSPAIMSASPGEKVTMCSASSSWYHWFQEQSGTPKRIYDTSKLASGVPARL 61
 Db 24 IVLTOSPAIMSASPGEKVTMCSASSSWYHWFQEQSGTPKRIYDTSKLASGVPARF 83

QY 62 SGSGSGTEFTLEISRVAEDVGVYCCQOLVEYPLTGAFTKLELKRAADAPTVSIF 117
 Db 84 RGSGSGTTSYLSITSGMEAEDAATYVCCQWSSNPFITFGSGTKLEINRADTAPTVSIF 139

QY 2 IELTOSPAIMSASPGEKVTMCSASSSWYHWFQEQSGTPKRIYDTSKLASGVPARL 61
 Db 24 IVLTOSPAIMSASPGEKVTMCSASSSWYHWFQEQSGTPKRIYDTSKLASGVPARF 83

QY 62 SGSGSGTEFTLEISRVAEDVGVYCCQOLVEYPLTGAFTKLELKRAADAPTVSIF 117
 Db 84 RGSGSGTTSYLSITSGMEAEDAATYVCCQWSSNPFITFGSGTKLEINRADTAPTVSIF 139

QY 2 IELTOSPAIMSASPGEKVTMCSASSSWYHWFQEQSGTPKRIYDTSKLASGVPARL 61
 Db 24 IVLTOSPAIMSASPGEKVTMCSASSSWYHWFQEQSGTPKRIYDTSKLASGVPARF 83

QY 62 SGSGSGTEFTLEISRVAEDVGVYCCQOLVEYPLTGAFTKLELKRAADAPTVSIF 117
 Db 84 RGSGSGTTSYLSITSGMEAEDAATYVCCQWSSNPFITFGSGTKLEINRADTAPTVSIF 139

QY 2 IELTOSPAIMSASPGEKVTMCSASSSWYHWFQEQSGTPKRIYDTSKLASGVPARL 61
 Db 24 IVLTOSPAIMSASPGEKVTMCSASSSWYHWFQEQSGTPKRIYDTSKLASGVPARF 83

QY 62 SGSGSGTEFTLEISRVAEDVGVYCCQOLVEYPLTGAFTKLELKRAADAPTVSIF 117
 Db 84 RGSGSGTTSYLSITSGMEAEDAATYVCCQWSSNPFITFGSGTKLEINRADTAPTVSIF 139

QY 2 IELTOSPAIMSASPGEKVTMCSASSSWYHWFQEQSGTPKRIYDTSKLASGVPARL 61
 Db 24 IVLTOSPAIMSASPGEKVTMCSASSSWYHWFQEQSGTPKRIYDTSKLASGVPARF 83

QY 62 SGSGSGTEFTLEISRVAEDVGVYCCQOLVEYPLTGAFTKLELKRAADAPTVSIF 117
 Db 84 RGSGSGTTSYLSITSGMEAEDAATYVCCQWSSNPFITFGSGTKLEINRADTAPTVSIF 139

QY 2 IELTOSPAIMSASPGEKVTMCSASSSWYHWFQEQSGTPKRIYDTSKLAS

STRANDBEDNESS: single
TOPOLOGY: linear
US-08-973-518-4

Alignment Scores:
pred. No.: 8.92e-59
Score: 531.50
Percent Similarity: 88.43%
Best Local Similarity: 85.12%
Query Match: 78.97%
DB: 3

US-10-049-868A-2 (1-363) x US-08-973-518-4 (1-140)

Qy 1 CAGGTGCAGCTGCAGGAGTCTGACCTGGCTGGGCCCTCACAGGCCTGTCATC 60
Db 21 GinvalLeuLysGluSerGlyProValLeuValAlaProSerGinSerLeuSerIleThr 40

Qy 61 ACTTGCACTGTCCTGGGATTCAAAACAGATATGGTTACACTGGGTCCAGCCTCA 120
Db 41 ThrcyThrValSerGlyPheSerLeuThrSerTyrGlyValHisTrpValArgGlnPro 60

Qy 121 CCAGGAAGGGTCTGGAGTGGCAGTATAATGGACTGGTGGAGCACAAATTATAAT 180
Db 61 ProGlyLysGlyLeuGluTrpLeuGlyValLeuTrpAlaGlyGlySerIleAsnTyrAsn 80

Qy 181 TCGGCTCTCATGTCAGACTGAGCATCAGCAAAGACAATCCAAAGGCCAAGTTCTTA 240
Db 81 SerAlaLeuMetSerArgLeuSerIleSerLysAspSerAspSerGinValPheLeu 100

Qy 241 AAAATGACAGTCTGCAGACTGATGACACAGCCATGACTACTGGCCAGAGATCGATCT 300
Db 101 LysMetSerSerLeuGinInthrAspSerThrAlaMetTyrTyrCysAlaArgAlaTyrGly 120

Qy 301 ACTATGATTAAGGCTATGGACTACTGGGCCAGGGACACGGTCACCGTCTCC 360
Db 121 AspTyrVal--HisTyrAlaMetAspTyrTrpGlyGlyGlyThrSerValThrValSer 139

Qy 361 TCA 363

Db 140 Ser 140

RESULT⁹
5455030-15

; Patent No. 5455030
; APPLICANT: LADNER, ROBERT C.; BIRD, ROBERT E.; HARDMAN, KARL
; TITLE OF INVENTION: IMMUNOTHERAPY USING SINGLE CHAIN
; POLYPEPTIDE BINDING MOLECULES
; NUMBER OF SEQUENCES: 24

; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/40,440
; FILING DATE: 1-APR-1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 512,910
; FILING DATE: 25-APR-1990
; APPLICATION NUMBER: 299,617
; FILING DATE: 19-JAN-1989
; APPLICATION NUMBER: 92,110
; FILING DATE: 02-SEP-1987
; APPLICATION NUMBER: 902,971
; FILING DATE: 01-SEP-1986
; SEQ ID NO:15:
; LENGTH: 242
; 5455030-15

Alignment Scores:
Pred. No.: 2.02e-58
Score: 529.50
Percent Similarity: 90.00%
Best Local Similarity: 85.83%
Query Match: 78.68%
DB: 6

US-10-049-868A-2 (1-363) x 5455030-15 (1-242)

Qy 4 GTGCAGCTGCAGGAGTCTGGACCTGGCTGGCCCTCACAGAGCCTGTCATC 63
Db 124 ValGinLeuLysGluSerGlyProValLeuValAlaProSerGinSerLeuSerIleThr 143

Qy 64 TGCACTGTCCTGGGATTCAAAACAGATATGGTTACACTGGGTCCAGCCTCA 123
Db 144 CysThrValSerGlyPheSerLeuThrAsnTyrGlyValHisTrpValArgGlnPro 163

Qy 124 GGAAGGGTCTGGAGTGGCTGGAGATAATGGACTGGTGGAGCACAAATTATAATCG 183
Db 164 GlyLysGlyLeuGluTrpLeuGlyValLeuTrpAlaGlyGlyAsnThrAsnTyrAsn 183

Qy 184 GCTCTCATGTCAGACTGAGCATCAGCAAAGACAATCCAAAGGCCAAGTTCTTA 243
Db 184 AlaLeuMetSerArgLeuSerIleSerLysAspSerAspSerGinValPheLeuLys 203

Qy 244 ATGACAGTCTGCAGACTGATGACACAGCCATGACTACTGGCCAGAGATCGATCT 303
Db 204 MetAsnSerLeuGinIleAspAspSerThrAlaIleTyrTyrCysAlaLys--ArgLeuGlu 222

Qy 304 ATGATTACGGCCATTGACTACTGGGCCAGGGACACGGTCACCGTCTCC 363
Db 223 ArgIlePheTyrTyrAlaMetAspTyrTrpGlyGlyGlyThrSerValThrValSer 242

RESULT 10
US-08-881-037-67
; Sequence 67, Application US/08881037
; Patent No. 6080588

GENERAL INFORMATION:
APPLICANT: Glick, Gary D.
APPLICANT: Swanson, Patrick C.
TITLE OF INVENTION: DNA BINDING ANTIBODIES
NUMBER OF SEQUENCES: 113
CORRESPONDENCE ADDRESS:
ADDRESSEE: Morrison & Foerster
STREET: 755 Page Mill Road
CITY: Palo Alto
STATE: CA
COUNTRY: USA
ZIP: 94304-1018

COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.30

CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/881,037
FILING DATE: 23-JUN-1997
CLASSIFICATION: 530
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/443,540
FILING DATE: 18-MAY-1995
CLASSIFICATION: 530
ATTORNEY/AGENT INFORMATION:
NAME: Konski, Antoinette F.
REGISTRATION NUMBER: 34,202
REFERENCE/DOCKET NUMBER: 203442110710
TELECOMMUNICATION INFORMATION:
TELEPHONE: (650) 813-5600
TELEFAX: (650) 494-0792

TELEX:
INFORMATION FOR SEQ ID NO: 67:
SEQUENCE CHARACTERISTICS:
LENGTH: 121 amino acids
TYPE: amino acid
STRANDBEDNESS: single
TOPOLOGY: linear
US-08-881-037-67

Alignment Scores:
Pred. No.: 4.84e-58 Length: 121

REGISTRATION NUMBER: 34,202
 REFERENCE/DOCKET NUMBER: 203442110710
 TELECOMMUNICATION INFORMATION:
 TELEPHONE: (650) 813-5600
 TELEFAX: (650) 494-0792
 TELEX:
 INFORMATION FOR SEQ ID NO: 67:
 SEQUENCE CHARACTERISTICS:
 LENGTH: 121 amino acids
 TYPE: amino acid
 STRANDEDNESS: single
 TOPOLOGY: linear
 US-08-881-037-67

Query Match 83.4%; Score 529.5; DB 6; Length 242;
 Best Local Similarity 85.8%; Pred. No. 5.7e-47;
 Matches 103; Conservative 5; Mismatches 11; Indels 1; Gaps 1;

QY 2 VOLQESGPGLVAPSQSIISITCTVSGISINRNYGVHWRQPPGKGLEWLGVIVTGGSTNYS 61
 Db 124 VOLKESGPVLPVAPSQSIISITCTVSGFSLTVYGVHWRQPPGKGLEWLGVIVAGGNTNYS 183

QY 62 ALMSRLSISKDNKSQVFLKMNLSQTDDTAMYCARDRS-TMITAYAMDYWGQGTIVTSS 121
 Db 184 ALMSRLSISKDNKSQVFLKMNLSQDDTAMYCAK-RLERIFYYAMDYWGQGTIVTSS 242

RESULT 10
 US-08-881-037-67
 Sequence 67, Application US/08881037
 ; Patent No. 6088588

GENERAL INFORMATION:
 APPLICANT: Glick, Gary D.
 APPLICANT: Swanson, Patrick C.
 TITLE OF INVENTION: DNA BINDING ANTIBODIES
 NUMBER OF SEQUENCES: 113
 CORRESPONDENCE ADDRESS:
 ADDRESSEE: Morrison & Foerster
 STREET: 755 Page Mill Road
 CITY: Palo Alto
 STATE: CA
 COUNTRY: USA
 ZIP: 94304-1018

COMPUTER READABLE FORM:
 MEDIUM TYPE: FLOPPY disk
 COMPUTER: IBM PC compatible
 OPERATING SYSTEM: PC-DOS/MS-DOS
 SOFTWARE: PatentIn Release #1.0, Version #1.30

CURRENT APPLICATION DATA:
 APPLICATION NUMBER: US/08/881, 037
 FILING DATE: 23-JUN-1997
 CLASSIFICATION: 530

PRIOR APPLICATION DATA:
 APPLICATION NUMBER: US 08/443, 540
 FILING DATE: 18-MAY-1995
 CLASSIFICATION: 530

ATTORNEY/AGENT INFORMATION:
 NAME: Konski, Antoinette F.

Query Match 82.8%; Score 525.5; DB 3; Length 121;
 Best Local Similarity 86.0%; Pred. No. 6.4e-47;
 Matches 104; Conservative 2; Mismatches 14; Indels 1; Gaps 1;

QY 1 QVOLQESGPGLVAPSQSIISITCTVSGISINRNYGVHWRQPPGKGLEWLGVIVTGGSTNYS 60
 Db 1 QVQLESGPVLVAPSQSIISITCTVSGFSLTVYGVHWRQPPGKGLEWLGVIVAGGNTNYS 60

QY 61 SALMSRLSISKDNKSQVFLKMNLSQTDDTAMYCARDRS-TMITAYAMDYWGQGTIVTSS 119
 Db 61 SALMSRLSISKDNKSQVFLKMNLSQDDTAMYCAK-RLERIFYYAMDYWGQGTIVTSS 120

QY 120 S 120
 Db 121 S 121

RESULT 11
 US-08-667-769A-15
 Sequence 15, Application US/08667769A
 ; Patent No. 5783184

GENERAL INFORMATION:
 APPLICANT: Ames, Robert S.
 APPLICANT: Appelbaum, Edward R.
 APPLICANT: Chaiken, Irwin M.
 APPLICANT: Cook, Richard M.
 APPLICANT: Gross, Mitchell S.
 APPLICANT: Holmes, Stephen D.
 APPLICANT: McMillan, Lynette J.
 APPLICANT: Theisen, Timothy W.

TITLE OF INVENTION: Recombinant IL5 Antagonists Useful in Treatment of IL5 Mediated Disorders
 NUMBER OF SEQUENCES: 76

CORRESPONDENCE ADDRESS:
 ADDRESSEE: SmithKline Beecham Corp./Corporate
 STREET: P.O. Box 1539-UW2220
 CITY: King of Prussia
 STATE: Pennsylvania
 COUNTRY: USA
 ZIP: 19406-0939

COMPUTER READABLE FORM:
 MEDIUM TYPE: Floppy disk
 COMPUTER: IBM PC compatible
 OPERATING SYSTEM: PC-DOS/MS-DOS
 SOFTWARE: PatentIn Release #1.0, Version #1.30

CURRENT APPLICATION DATA:
 APPLICATION NUMBER: US/08/667, 769A
 FILING DATE:
 CLASSIFICATION: 424

PRIOR APPLICATION DATA:
 APPLICATION NUMBER: PCT/US95/17082
 FILING DATE: 22-DEC-1995

PRIOR APPLICATION DATA:
 APPLICATION NUMBER: US 08/470110
 FILING DATE: 06-JUN-1995

PRIOR APPLICATION DATA:
 APPLICATION NUMBER: US 08/467420
 FILING DATE: 06-JUN-1995

PRIOR APPLICATION DATA: